<DOC>
	<DOCNO>NCT01970215</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy different dose TA-8995 , cholesteryl ester transfer protein ( CETP ) inhibitor , elevation high-density lipoprotein cholesterol ( HDL-C ) reduction low-density lipoprotein cholesterol ( LDL-C ) , alone combination statin therapy . The secondary objective study determine safety tolerability TA-8995 patient mild dyslipidaemia .</brief_summary>
	<brief_title>TA-8995 : Its Use Patients With Mild Dyslipidaemia ( TULIP )</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Fasting LDLC level &gt; 2.5 mmol/L &lt; 4.5 mmol/L , HDLC level &lt; 1.8 mmol/L &gt; 0.8 mmol/L , TG level &lt; 4.5 mmol/L run washout exist therapy Not lipidaltering therapy screen lipidaltering treatment regimen screen Body mass index &gt; 32 kg/m2 ; Participation another clinical study involve investigational market drug within 30 day prior enrolment ( Visit 2 ) ; Any clinical manifestation atherosclerotic vascular disease ; Diagnosis type 1 diabetes ; Uncontrolled type 2 diabetes : haemoglobin A1c &gt; 8 % ; Uncontrolled hypertension : sit systolic blood pressure &gt; 160 mmHg and/or sit diastolic blood pressure &gt; 90 mmHg ; History hyperaldosteronism ; Active muscle disease persistent creatine kinase concentration &gt; 3 Ã— upper limit normal ( ULN ) . One retest allow 1 week verify result ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>